Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type

Hoffmann, Martha; Kletter, Kurt; Diemling, Markus; Becherer, Alexander; Pfeffel, Franz; Petkov, Ventzislav; Chott, Andreas; Raderer, Markus

doi:10.1023/a:1008312726163

Cited by 153 publications

(60 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In 2 of their articles, Hoffmann et al reported poor tracer uptake in patients with MALT. 27,28 In contrast, Beal et al reported that MALT lymphoma could be detected with 18 F-FDG-PET in approximately 70% to 80% of patients and that there was no difference in detection between patients with lymph node and extranodal disease sites. 18 Our study, which, to our knowledge, includes the largest number of patients to date, supports the latter observation.…”

Section: Discussionmentioning

confidence: 97%

The usefulness of ¹⁸F‐fluorodeoxyglucose positron emission tomography (¹⁸F‐FDG‐PET) and a comparison of ¹⁸F‐FDG‐pet with ⁶⁷gallium scintigraphy in the evaluation of lymphoma

Tsukamoto

Kojima

Hasegawa

et al. 2007

Cancer

189

101

View full text Add to dashboard Cite

BACKGROUND.Although studies comparing conventional imaging modalities with 18F‐fluorodeoxyglucose positron emission tomography (18F‐FDG‐PET) for the detection of lymphoma and although the relations between 18F‐FDG‐PET and histologic types were reported previously, most studies were not systematic and involved relatively small numbers of patients.METHODS.Two hundred fifty‐five patients with lymphoma had their disease staged using 18F‐FDG‐PET, and 191 of those patients also were assessed using gallium‐67 scintigraphy (67Ga). Disease sites were identified on a site‐by‐site basis using computed tomography scans and/or magnetic resonance imaging. The results of these conventional imaging modalities were compared with the results from 8F‐FDG‐PET and 67Ga, and correlations between the imaging results and pathologic diagnoses were evaluated by using the World Health Organization classification system.RESULTS.Of 913 disease sites in 255 patients, 18F‐FDG‐PET identified >97% of disease sites of Hodgkin lymphoma (HL) and aggressive and highly aggressive non‐Hodgkin lymphoma. For indolent lymphoma, the detection rate of 18F‐FDG‐PET was 91% for follicular lymphoma (FL); 82% for extranodal marginal zone B‐cell lymphoma of mucosa‐associated lymphoid tissue, irrespective of plasmacytic differentiation; and approximately 50% for small lymphocytic lymphoma (SLL) and splenic marginal zone lymphoma (SMZL). The results from 67Ga were similar to those from 18F‐FDG‐PET for most histologic subtypes. However, the sensitivity of 67Ga was unexpectedly poor for FL, for mantle cell lymphoma (MCL), and for the nasal type of natural killer/T‐cell lymphoma (NK/T‐nasal), ranging from 30% to 38%.CONCLUSIONS.18F‐FDG‐PET was useful for all histologic subtypes of lymphoma other than SLL and SMZL. Compared with 67Ga, the authors strongly recommend the use of 18F‐FDG‐PET in patients with FL, MCL, and NK‐nasal. Cancer 2007. © 2007 American Cancer Society.

show abstract

Section: Discussionmentioning

confidence: 97%

The usefulness of ¹⁸F‐fluorodeoxyglucose positron emission tomography (¹⁸F‐FDG‐PET) and a comparison of ¹⁸F‐FDG‐pet with ⁶⁷gallium scintigraphy in the evaluation of lymphoma

Tsukamoto

Kojima

Hasegawa

et al. 2007

Cancer

189

101

View full text Add to dashboard Cite

show abstract

“…Previous studies evaluating the sensitivity of FDG-PET in lymphomas showed conflicting results, particularly in indolent lymphomas. [5][6][7][8][9][10][11] We hypothesized that biologic differences between specific pathologic subtypes of lymphoma result in different degrees of FDG uptake and that utility of FDG-PET imaging varies between specific lymphomas. We retrospectively studied results of FDG-PET scans in patients with lymphoma using the World Health Organization (WHO) classification system to identify the specific subtypes reliably detected by FDG-PET.…”

Section: Introductionmentioning

confidence: 99%

Utility of FDG-PET scanning in lymphoma by WHO classification

Elstrom

Guan

Baker

et al. 2003

Blood

403

213

View full text Add to dashboard Cite

We retrospectively evaluated 18 fluoro-2-deoxyglucose positron emission tomography (FDG-PET) scans in 172 patients with lymphoma and correlated results with pathologic diagnosis using the World Health Organization (WHO) classification system. In total, FDG-PET detected disease in at least one site in 161 patients (94%) and failed to detect disease in 11 patients (6%). The most frequent lymphoma diagnoses were diffuse large Bcell lymphoma (LBCL; n ‫؍‬ 51), Hodgkin lymphoma (HL; n ‫؍‬ 47), follicular lymphoma (FL; n ‫؍‬ 42), marginal zone lymphoma (MZL; n ‫؍‬ 12), mantle cell lymphoma (MCL; n ‫؍‬ 7), and peripheral T-cell lymphoma (PTCL; n ‫؍‬ 5

show abstract

“…Whereas follicular lymphomas are FDG-avid in approximately 98% of cases, only 8/12 cases (67%) of (low-grade) marginal zone lymphoma were detected on PET in this series [73]. None of 10 cases of extranodal marginal zone lymphoma were detected by PET in another series [75]. Small lymphocytic lymphoma/chronic lymphocytic leukemia is also only variably FDG-avid, although a maximum standardized uptake value greater than 5 may raise suspicion for a large cell transformation [76].…”

Section: False Positives and Negativesmentioning

confidence: 53%

FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma

Kasamon

Wahl²

2008

Current Opinion in Oncology

View full text Add to dashboard Cite

Purpose of review-The prognostic utility of midtreatment fluorine-18 fluorodeoxyglucose positron emission tomography ( 18 F-FDG PET) has become widely appreciated in aggressive Bcell non-Hodgkin's lymphoma and, more recently, in Hodgkin's lymphoma. Outcomes based on midtreatment FDG PET performed during primary and salvage therapy are reviewed and management strategies considered, with a focus on treatment intensification for poor-risk disease as identified by metabolic imaging.Recent findings-PET, when performed after as few as two cycles of primary chemotherapy, is strongly prognostic in certain aggressive lymphomas and provides information independently from validated prognostic indices. What constitutes a positive or negative scan is not always clear, particularly if there is minimal tracer uptake, and the causes of false positive and false negative scans must be considered. How to tailor therapy based on the midtreatment PET result is the focus of current trials and is presently being defined for both Hodgkin's and non-Hodgkin's lymphoma. Summary-EarlyPET has the strong potential to improve clinical outcomes by sparing goodrisk patients from overly aggressive treatments, and by more accurately identifying poor-risk patients so as to guide changes in management. Treatment modifications on the basis of midtreatment PET are presently best made in clinical trial settings.

show abstract

Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type

Abstract: These discouraging results indicated that WB-FDG-PET is not useful for staging and follow-up of MALT-type lymphoma, and should therefore not be included in the clinical decision making process.

Cited by 153 publications

References 15 publications

The usefulness of ¹⁸F‐fluorodeoxyglucose positron emission tomography (¹⁸F‐FDG‐PET) and a comparison of ¹⁸F‐FDG‐pet with ⁶⁷gallium scintigraphy in the evaluation of lymphoma

The usefulness of ¹⁸F‐fluorodeoxyglucose positron emission tomography (¹⁸F‐FDG‐PET) and a comparison of ¹⁸F‐FDG‐pet with ⁶⁷gallium scintigraphy in the evaluation of lymphoma

Utility of FDG-PET scanning in lymphoma by WHO classification

FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma

Contact Info

Product

Resources

About

Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type

Abstract: These discouraging results indicated that WB-FDG-PET is not useful for staging and follow-up of MALT-type lymphoma, and should therefore not be included in the clinical decision making process.

Cited by 153 publications

References 15 publications

The usefulness of 18F‐fluorodeoxyglucose positron emission tomography (18F‐FDG‐PET) and a comparison of 18F‐FDG‐pet with 67gallium scintigraphy in the evaluation of lymphoma

The usefulness of 18F‐fluorodeoxyglucose positron emission tomography (18F‐FDG‐PET) and a comparison of 18F‐FDG‐pet with 67gallium scintigraphy in the evaluation of lymphoma

Utility of FDG-PET scanning in lymphoma by WHO classification

FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma

Contact Info

Product

Resources

About

The usefulness of ¹⁸F‐fluorodeoxyglucose positron emission tomography (¹⁸F‐FDG‐PET) and a comparison of ¹⁸F‐FDG‐pet with ⁶⁷gallium scintigraphy in the evaluation of lymphoma

The usefulness of ¹⁸F‐fluorodeoxyglucose positron emission tomography (¹⁸F‐FDG‐PET) and a comparison of ¹⁸F‐FDG‐pet with ⁶⁷gallium scintigraphy in the evaluation of lymphoma